Research · 9 min read
What a Microdose or Starter GLP-1 Program Actually Is
Microdose, low dose and starter are names a seller chose. None of them appears in the approved labeling for any of these medications, and knowing what the word is attached to changes how you read a price.
Key takeaways
- Microdose, low dose and starter are commercial names; none appears in the approved labeling of the four products checked.
- All four labels describe a stepwise dosage escalation and state its purpose as reducing the risk of gastrointestinal adverse reactions.
- The tirzepatide weight-management labeling states its starting dosage is for treatment initiation and is not approved as a maintenance dosage.
- These programs are generally compounded, and a compounded preparation is not confined to a list of labeled strengths because it has no approved label.
- FDA has noted that compounded semaglutide concentrations vary by compounder, so the program name discloses no quantity — ask what concentration is supplied.
- A microdose figure set beside a full-strength flat rate is a comparison between two different purchases.
Answer first: it is a product name, not a labeled category
Microdose, micro-dosing, low dose and starter are commercial names. They describe a tier a company decided to sell. They are not terms of art from a drug label, and they are not a category any regulator defines.
The four approved labels checked here were the semaglutide injection and tablet labeling, the semaglutide labeling for glycemic control, and the two tirzepatide labelings. The word microdose does not appear in any of them. Neither does low dose, and neither does starter. What does appear, in all four, is a stepwise escalation with a written purpose.
That gap is the whole subject. A reader comparing a microdose price against a standard price is comparing a name from a marketing page against a strength from a label, and those two things are not the same kind of object.
What the approved labels describe instead
Every one of these labels sets out a schedule that begins at a low quantity and increases in steps. The instruction is not left as a bare table. Each label states why the schedule exists, and the four state it in almost identical words: follow the dosage escalation to reduce the risk of gastrointestinal adverse reactions.
The tirzepatide weight-management labeling is blunter still about where the schedule starts. It states that the starting dosage is for treatment initiation and is not approved as a maintenance dosage. That is the label describing its own beginning as a beginning.
The labels also leave room for people to differ. They direct that treatment response and tolerability be considered when selecting the maintenance dosage. Where a quantity is not tolerated, they describe delaying an increase, or considering a lower maintenance dosage. So the documents do contemplate settling at different points. What they do not contain is a treatment approach built around staying below where the schedule begins.
Why these programs are almost always compounded
There is a structural reason the word shows up on compounded products and not on approved ones. An approved product is supplied in fixed labeled strengths. Each strength is printed on the carton and each one is part of what was approved.
A compounded preparation is a different kind of object. Section 503A of the federal food and drug law describes when a compounded drug is exempt from premarket approval, from manufacturing practice requirements, and from labeling with adequate directions for use. One of its conditions is that the drug is compounded for an identified individual patient, based on the receipt of a valid prescription order.
A preparation made against one person's prescription is not confined to a list of labeled strengths, because there is no approved label setting that list. That is the mechanism. It is a statement about what the legal category permits, and it is not a statement that any particular quantity is a good idea.
The vial, not the program name, is where the amount lives
FDA has described what varies across compounded semaglutide products. Product concentrations may differ depending on the compounder, and a single compounder may offer several concentrations. The agency has also noted that accompanying instructions, where they are provided at all, may be written in units rather than in milligrams or milliliters.
That matters for anyone shopping on the word. Two programs both advertised as microdose are not thereby the same thing. The quantity you receive is a function of the concentration the pharmacy prepared and the volume you are told to draw, and neither of those is disclosed by the program's name.
The same alert is the reason the physical object deserves its own reading. What arrives in the box, how it is labeled, and how a dose is measured out of a multiple-dose vial are covered separately here. Read that alongside any program sold on a low entry figure.
What the low headline number is usually attached to
A microdose tier is frequently the cheapest line on a pricing page, and it is often the figure the advertising is built around. That is a legitimate thing to sell. It becomes a problem only when the figure travels into a comparison without its qualifier.
Set a microdose figure beside a flat rate that covers every strength a program supplies, and the microdose number wins on the page while buying something narrower. The honest comparison prices the same thing at both sellers, or states plainly that it is not doing so.
Ask what the figure becomes if a clinician later recommends moving up. Some programs hold one price across every strength. Some price each step separately. A low entry figure attached to the first of those is a different proposition from the same figure attached to the second.
What nobody can tell you from a program name
No approved labeling describes a microdose approach, so there is no labeled account of what one achieves. None is cited below, because none of the sources read supports one. An advertisement that fills that silence with a benefit is making a claim it has to be able to substantiate.
FDA has told telehealth companies directly not to describe a compounded drug as the same as an FDA-approved drug, or as a generic version of one. Generic drugs are approved by FDA before marketing; compounded drugs are not reviewed by FDA for safety, effectiveness or quality at all.
Whether a smaller quantity is appropriate for you is a clinical question, and it belongs to the prescriber who is treating you and to the instructions that come with your own product. What a comparison site can settle is narrower and still useful: what the word means commercially, what the labels actually say, and what the price is attached to.
Questions that turn a program name into a fact
Which molecule is in it, and is the product compounded or FDA-approved. That one question separates two very different purchases, and it is answerable in a sentence.
Which pharmacy prepares it, at what concentration, and how much arrives per shipment. Ask for the concentration specifically. A program that prices by month rather than by strength may still supply different concentrations at different points.
Whether there is a path upward, what it costs at each step, and what happens to the current billing period if a change is made mid-cycle. And who to contact about administration instructions once the vial is in your hand, since a compounded preparation does not arrive with a manufacturer's leaflet.
Sources
- WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use — full prescribing informationThat the labeling directs the reader to follow the dosage escalation to reduce the risk of gastrointestinal adverse reactions, for both the injection and the tablet; that it directs consideration of treatment response and tolerability when selecting the maintenance dosage; that it describes delaying an escalation where a dose is not tolerated; and that the words microdose, low dose and starter do not appear anywhere in it.
- ZEPBOUND (tirzepatide) injection, for subcutaneous use — full prescribing informationThat the labeling states its starting dosage is for treatment initiation and is not approved as a maintenance dosage; that it directs following the dosage escalation for all indications to reduce the risk of gastrointestinal adverse reactions; that it directs consideration of treatment response and tolerability in selecting the maintenance dosage and describes considering a lower maintenance dosage where one is not tolerated; and that the words microdose, low dose and starter do not appear anywhere in it.
- MOUNJARO (tirzepatide) injection, for subcutaneous use — full prescribing informationThat the labeling directs following the starting dosage recommendation and the dosage escalation schedule to reduce the risk of gastrointestinal adverse reactions, and that the words microdose, low dose and starter do not appear anywhere in it.
- OZEMPIC (semaglutide) injection, for subcutaneous use — full prescribing informationThat the labeling directs following the dosage escalation to reduce the risk of gastrointestinal adverse reactions, and that the words microdose, low dose and starter do not appear anywhere in it.
- 21 U.S.C. 353a — Pharmacy compoundingThat the section's exemptions apply to a drug product compounded for an identified individual patient based on the receipt of a valid prescription order, or on a prescriber-approved notation that a compounded product is necessary for the identified patient, and that the exemptions named in subsection (a) are from the premarket approval, manufacturing practice and adequate-directions-for-use provisions.
- FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide productsThat product concentrations may vary depending on the compounder and that a single compounder may offer multiple concentrations of compounded semaglutide products, and that instructions accompanying a compounded drug, where provided, may direct administration in units rather than in milligrams or milliliters.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossThat compounded drugs are not FDA approved and are not reviewed by the agency for safety, effectiveness or quality before marketing, and that a claim that a compounded drug is the same as an FDA-approved drug is listed among the warning signs for consumers.
- FDA to Telehealth Companies: What to Know When Promoting Compounded DrugsThat the agency reminds telehealth companies not to describe a compounded drug as a generic version of an FDA-approved drug or as the same as a drug approved by FDA, and states that generic drugs are approved by FDA before marketing.
Frequently asked questions
Is microdosing an official medical term for these drugs?
Not in the labeling. The word does not appear in the approved prescribing information for the semaglutide injection and tablet products, the semaglutide product labeled for glycemic control, or either tirzepatide product. Those four labels were read in full and searched directly. What they describe is a stepwise dosage escalation with a stated purpose, which is a different concept from a program built around a low quantity.
Why does a microdose program cost so much less?
Because it is a narrower product, and usually a compounded one. A figure attached to a low quantity is not the price of a full course of treatment, and the two are frequently placed side by side as though they were. Before comparing, establish which molecule you are buying, whether it is compounded or approved, and what the price becomes at every step the program supplies.
Do the approved labels say anything about staying at a low amount?
They direct that treatment response and tolerability be considered when selecting the maintenance dosage, and they describe delaying an increase or considering a lower maintenance dosage where a quantity is not tolerated. The tirzepatide weight-management labeling also states that its starting dosage is for treatment initiation and is not approved as a maintenance dosage. Those are statements about the labeled product, and the schedule that applies to you comes from your prescriber.
Are two microdose programs the same amount of medication?
Not necessarily, and there is no way to tell from the name. FDA has noted that concentrations of compounded semaglutide may vary by compounder, and that a single compounder may offer more than one. Instructions may also be written in units rather than milligrams or milliliters. Ask what concentration is supplied and how much arrives per shipment, and get the answer before you enter a card.
Is a compounded microdose the same drug as the brand product?
It is not the same product, and FDA has told telehealth companies not to describe a compounded drug as the same as an FDA-approved drug or as a generic version of one. Generic drugs go through FDA approval before they are marketed. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing at all, which is the difference the word compounded is carrying.
Should I start on a microdose program to see how I tolerate it?
That is a decision for the clinician who is treating you, and it depends on things a website cannot see. What is worth raising at the appointment is the same set of facts set out above: which product a program supplies, whether it is compounded, what the escalation path is, and what each step costs. Take those answers into the conversation rather than a program's own description of itself.